Medgenics(Regs) Share Discussion Threads

[sicilian_kan] 12/3/2010 08:27

Header updated.

[sicilian_kan] 11/3/2010 08:19

I make the current market cap just £8.8m, though I'm not sure of the current MEDG/MEDU split.

How can this be right for the potential here with the world expert on liver disease having joined, the 16 months without an EPO injection and the deal with a leading world company in hemophilia.

[sicilian_kan] 11/3/2010 08:09

For any readers, I have not been going along with the ramping on TMC and smellyjim does not like that and has come over from that board to here with no knowledge of this share.

[sicilian_kan] 09/3/2010 22:14

sj, just 10% dilution from the fundraising with $750k raised at 5p and 6.5p, with $5m due or paid from non-dilutory forms e.g. grants and contractual monies earned. Hardly fair to say that they dilute often and cheaply. For AIM, it looks very good to me.

[smellyjim] 09/3/2010 22:12

It's also staggering how they like to dilute often and cheaply.

[sicilian_kan] 09/3/2010 22:11

smellyjim, please explain...as far as I can see, this company has more than massive potential, it is proving itself in trials and in negotiating multi-million pound deals with a tiny market cap...

[smellyjim] 09/3/2010 22:11

lol! One to steer well clear of then.

[sicilian_kan] 09/3/2010 22:04

In short, it is staggering that this company is valued at just £8m! It has got $5.3m alone in up front non-dilutative funding this year, with multiple-blockbuster. If this said cancer treatment, the hoardes would be here now and the m/c would be £50m-£70m already. Yet the potential economics are the same and the treatment is working in trials and a market leader in hemophilia is paying for medgenics to develop it something. I'm surprised this is where it is. It won't be here for ever.

[sicilian_kan] 09/3/2010 22:01

Final comments in the RNS are good too:

"We believe that the Biopump, once fully developed, will represent the ultimate
in personalised medicine, offering a new and cost effective way to both
manufacture and deliver therapeutic proteins directly in the patient on an
extended basis and thus provide a better and safer protein therapy compared to
serial injections and other alternatives and we look forward to updating the
market with further positive news throughout 2010."

[sicilian_kan] 09/3/2010 21:59

Fifth piece of good news in there:

This comment is great "The company further anticipates additional licensing activity and new programs in the product pipeline during 2010".

This means:

1. They expect in 2010 the licensing of EPODURE or INFRADURE, and it is likely to be the latter, which would get at least $10m up front with massive milestones and royalties (as the hemophilia treament to be developed for clinical got $4-6m up front and INFRADURE is way ahead of that. If it was EPODURE, we should get $30m up front with $500m milestones and at least 15% royalties.

2. By new programs in the product pipeline, this will mean either INFRADURE in Phase I, or the obesity treatment getting a hemophilia style deal.

[sicilian_kan] 09/3/2010 21:55

Fourth piece of good news in there:

Targets for the Phase I/II trial have been extended due to success:

When the trial started, the RNS said that the aim was to deliver EPO for 3-6 months. They were not even going to monitor people after 6 months! Now they state that the renewed trial is aimed at showing that the positive therapeutic effect will occur for six months or more.

[sicilian_kan] 09/3/2010 21:49

Third piece of good news in there:

All seven patients treated so far (six on the low dose) have had EPO successfully delivered. That is a 100% success rate in terms of the delivery from the tech. We also have confirmation that one patient now has had 16 months without weekly injections! This is an increase on the last report of 12 months. No adverse events have been reported.

This statement is also new, "even the lowest dose causing the levels of haemoglobin in most patients to be sustained for months within the target range without any EPO injections".

[sicilian_kan] 09/3/2010 21:45

Second piece of good news in there:

They have already received in just a few months, $2.6m for the preclinical biopump development for hemophilia (their third pipeline target). They should get another $1.4m by the end of 2010. In addition, they should get $1.3m from the Israeli government, meaning $5.3m in non-dilutative funding by end - 2010, which shows why so little needed to be raised this time and why the dilution has been minimal from this placing.

[sicilian_kan] 09/3/2010 13:08

First piece of good news in there:

The anemia Phase I/II trial will be restarting with the funds raised, testing the higher dose. Trial to start in Q2 10. As this is an open trial, there will be progress updates on the patients throughout, just as per the previous year. So there will be regular news.

[sicilian_kan] 09/3/2010 13:02

I've just seen the RNS from Friday, slipped in during the middle of the day. There is some very interesting and promising stuff in there, take a look:

[sicilian_kan] 25/2/2010 08:18

Last time there was partnership news (on a preclinical third in pipeline drug) the share price hit 12p. I would expect a similar reaction for INFRADURE and at least 20-30p should EPODURE be partnered. There are talks ongoing and news will come, but it won't come before the placing.

[crimeprotection1] 25/2/2010 00:40

Saw it happen a few weeks ago with a 25k sell, i guess mm's dont want any of the stock on there books when its simply not being traded! Shame coz all sounds v positive.

[dawsonpaul] 24/2/2010 09:58

Not sure why this drops tbh. Seems to be follow the market but then doesn't recover because there are no trades. Could play in favor. Watching carefully.

[andrbea] 12/2/2010 10:45

need to know how the Biopump is progressing

keeping my small holding till we do

[sicilian_kan] 11/2/2010 18:40

Hi dp,

What is interesting me at the moment is:

1. MEDU has a mid of 5.75p whilst MEDG has a mid of 7.125p. It might even be possible to make a profit switching over, but it's not a large enough one for me to bother about.

2. The MEDU mid is significantly below the price the directors are committing to buying at in the new placing (6.5p).

Once the placing is complete, I would hope for an update not too far thereafter.

[sicilian_kan] 08/2/2010 19:02

Does anyone still read here? Would be good to get more of a discussion going.

Interesting to see the second RNS today, with a company taking MEDG shares in lieu of payment, despite a placing being forthcoming shortly. Shows confidence by the company who must have been reassured they would be worth something decent.

[sicilian_kan] 08/2/2010 08:29

Good to see the share price holding steady on the news.

[sicilian_kan] 08/2/2010 07:09

More yet director buying and from three directors in a decently priced placing at 6.5p. All very promising.

Medgenics, Inc.

('Medgenics' or the 'Company')

8 February 2010

The Board of Medgenics announces that on 5 February 2010 it was informed that on that same date three of the Company's directors entered into an irrevocable agreement to purchase 192,591 common shares of US$ 0.0001 each ("Common Shares") in the Company at a price of 6.5 pence per Common Share. Joel Kanter and his related parties will acquire 48,148 Common Shares, Andrew Pearlman will acquire 48,148 Common Shares and Eugene Bauer will acquire 96,295 Common Shares for an aggregate consideration of £12,518.

The Company is currently in the midst of a fund raising round which it hopes to complete in the next few weeks. The Directors' purchase of Common Shares will be completed at the same time as the Company's current placing closes and their relevant shareholdings will be notified at such time.

[opmoc] 30/1/2010 01:07

Donate a Couple of Quid To The Children of Iraq



Tony